Department of Radiology
Animal Experimentation and Research | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Nervous System Diseases | Nutritional and Metabolic Diseases | Veterinary Medicine
beta-hexosaminidase is an enzyme responsible for the degradation of gangliosides, glycans, and other glycoconjugates containing beta-linked hexosamines that enter the lysosome. GM2 gangliosidoses, such as Tay-Sachs and Sandhoff, are lysosomal storage disorders characterized by beta-hexosaminidase deficiency and subsequent lysosomal accumulation of its substrate metabolites. These two diseases result in neurodegeneration and early mortality in children. A significant difference between these two disorders is the accumulation in Sandhoff disease of soluble oligosaccharide metabolites that derive from N- and O-linked glycans. In this paper we describe our results from a longitudinal biochemical study of a feline model of Sandhoff disease and an ovine model of Tay-Sachs disease to investigate the accumulation of GM2/GA2 gangliosides, a secondary biomarker for phospholipidosis, bis-(monoacylglycero)-phosphate, and soluble glycan metabolites in both tissue and fluid samples from both animal models. While both Sandhoff cats and Tay-Sachs sheep accumulated significant amounts of GM2 and GA2 gangliosides compared to age-matched unaffected controls, the Sandhoff cats having the more severe disease, accumulated larger amounts of gangliosides compared to Tay-Sachs sheep in their occipital lobes. For monitoring glycan metabolites, we developed a quantitative LC/MS assay for one of these free glycans in order to perform longitudinal analysis. The Sandhoff cats showed significant disease-related increases in this glycan in brain and in other matrices including urine which may provide a useful clinical tool for measuring disease severity and therapeutic efficacy. Finally, we observed age-dependent increasing accumulation for a number of analytes, especially in Sandhoff cats where glycosphingolipid, phospholipid, and glycan levels showed incremental increases at later time points without signs of peaking. This large animal natural history study for Sandhoff and Tay-Sachs is the first of its kind, providing insight into disease progression at the biochemical level. This report may help in the development and testing of new therapies to treat these disorders.
Sphingolipids, Sheep, Occipital lobe, Tay-Sachs disease, Cats, Metabolites, Phospholipids, Urine
Rights and Permissions
Copyright: © 2020 Cavender et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI of Published Version
Cavender C, Mangini L, Van Vleet JL, Corado C, McCullagh E, Gray-Edwards HL, Martin DR, Crawford BE, Lawrence R. Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses. PLoS One. 2020 Dec 1;15(12):e0243006. doi: 10.1371/journal.pone.0243006. PMID: 33259552; PMCID: PMC7707493. Link to article on publisher's site
Cavender C, Mangini L, Van Vleet JL, Corado C, McCullagh E, Gray-Edwards HL, Martin DR, Crawford BE, Lawrence R. (2020). Natural history study of glycan accumulation in large animal models of GM2 gangliosidoses. Open Access Publications by UMMS Authors. https://doi.org/10.1371/journal.pone.0243006. Retrieved from https://escholarship.umassmed.edu/oapubs/4520
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Animal Experimentation and Research Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons, Nervous System Diseases Commons, Nutritional and Metabolic Diseases Commons, Veterinary Medicine Commons